AXGN Logo

AxoGen, Inc. (AXGN) 

NASDAQ
Market Cap
$688.29M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
558 of 960
Rank in Industry
66 of 120

Largest Insider Buys in Sector

AXGN Stock Price History Chart

AXGN Stock Performance

About AxoGen, Inc.

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM …

Insider Activity of AxoGen, Inc.

Over the last 12 months, insiders at AxoGen, Inc. have bought $0 and sold $980,900 worth of AxoGen, Inc. stock.

On average, over the past 5 years, insiders at AxoGen, Inc. have bought $188,940 and sold $2.2M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $62,240 was made by Wendell Amy McBride (director) on 2023‑09‑06.

List of Insider Buy and Sell Transactions, AxoGen, Inc.

2024-03-21SaleCEO
39,280
0.091%
$7.68$301,670+21.64%
2024-03-21SaleChief Innovation Officer
4,578
0.0106%
$7.68$35,159+21.64%
2024-03-21SaleChief R&D Officer
6,881
0.0159%
$7.68$52,846+21.64%
2024-03-21SaleVP Operations
6,033
0.014%
$7.68$46,333+21.64%
2024-03-07Saledirector
25,000
0.0581%
$9.00$225,000-0.55%
2024-03-07SaleVP Operations
36,310
0.0826%
$8.81$319,891-0.55%
2023-12-11SaleEVP & Chief Financial Officer
12,500
0.0291%
$7.50$93,809+18.97%
2023-09-06Purchasedirector
10,000
0.0235%
$6.22$62,240+16.26%
2023-08-23Purchasedirector
10,000
0.0234%
$6.56$65,600+7.44%
2023-08-16Purchasedirector
10,000
0.0252%
$6.11$61,100+23.36%
2023-06-01Saledirector
41,980
0.0994%
$8.71$365,780-18.63%
2023-05-23Saledirector
7,468
0.0176%
$9.23$68,899-21.55%
2023-02-01SaleEVP & Chief Financial Officer
14,550
0.0348%
$9.36$136,188-11.25%
2023-01-31SaleEVP & Chief Financial Officer
14,320
0.0343%
$9.55$136,756-12.94%
2023-01-30SaleEVP & Chief Financial Officer
14,111
0.0334%
$9.69$136,736-15.26%
2023-01-27SaleEVP & Chief Financial Officer
20,940
0.0495%
$10.16$212,750-19.29%
2022-11-16SaleEVP & Chief Financial Officer
10,649
0.027%
$11.88$126,510-24.25%
2022-11-14Saledirector
13,000
0.0339%
$12.74$165,620-27.03%
2022-11-08Saledirector
13,000
0.0337%
$12.50$162,500-25.66%
2022-08-10Sale
8,886
0.0204%
$9.70$86,159-4.15%

Insider Historical Profitability

12.63%
Zaderej Karen L.CEO
1124565
2.5553%
$15.6498+15.63%
Freitag Gregory Genedirector
271594
0.6171%
$15.64612+24.07%
Mandato Joseph Mdirector
1226773
2.7876%
$15.6414+61.29%
Hopfenspirger Larry10 percent owner
426066
0.9681%
$15.6410
Gold Mark Stephendirector
348761
0.7925%
$15.6451+18.2%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Arrowmark Colorado Holdings Llc$38.14M10.824.73M-8.26%-$3.43M0.1
BlackRock$26.08M7.43.23M-3.31%-$892,267.67<0.01
Morgan Stanley$25.67M7.283.18M+3.18%+$791,997.89<0.01
Soleus Capital Management, L.P.$25.06M7.113.11M+19.65%+$4.12M0.1
The Vanguard Group$19.46M5.522.41M-2.19%-$436,530.51<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.